Quarterly report pursuant to Section 13 or 15(d)

Organization, Plan of Business Operations (Details Textual)

v3.10.0.1
Organization, Plan of Business Operations (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended
Nov. 12, 2018
Sep. 30, 2018
Dec. 31, 2017
Retained Earnings (Accumulated Deficit)   $ (38,290) $ (20,661)
Subsequent Event [Member] | Line of Credit [Member]      
Initial Financing Amount $ 3,000    
Interim Financing Amount 7,000    
Subsequent Event [Member] | Second Closing [Member]      
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned 180,000    
Subsequent Event [Member] | InvaGen Pharmaceuticals Inc [Member]      
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned $ 35,000    
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares 5,833,333    
Business Acquisition, Share Price $ 6.00